IGFBP-2 enhances VEGF gene promoter activity and consequent promotion of angiogenesis by neuroblastoma cells

Endocrinology

Volumn 152, Issue 9, 2011, Pages 3332-3342

  Azar, Walid J ^a,b   Azar, Sheena H X ^a   Higgins, Sandra ^a,b   Hu, Ji Fan ^c   Hoffman, Andrew R ^c   Newgreen, Donald F ^a   Werther, George A ^a,b   Russo, Vincenzo C ^a,b  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALVASCULIN; COLLAGEN SPONGE; HEPARANASE; INTERLEUKIN 18; MESSENGER RNA; MYC PROTEIN; PROTEIN MYB; SMAD4 PROTEIN; SMAD5 PROTEIN; SMAD9 PROTEIN; SOMATOMEDIN BINDING PROTEIN 2; STAT3 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NFAT1; TRANSCRIPTION FACTOR NFAT2; TRANSCRIPTION FACTOR NFAT5; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN; ZINC FINGER PROTEIN;

ANGIOGENESIS; ARTICLE; CARCINOGENESIS; CELL FRACTIONATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHICK EMBRYO; CHORIOALLANTOIS; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; MICROVASCULARIZATION; NEUROBLASTOMA; NEUROBLASTOMA CELL; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UPREGULATION; WILD TYPE; ZYMOGRAPHY;

CELL FRACTIONATION; CELL LINE, TUMOR; GENE EXPRESSION REGULATION; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; NEOVASCULARIZATION, PATHOLOGIC; PROMOTER REGIONS, GENETIC; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80052474567     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-1121     Document Type: Article

References (62)

1. Russo VC, Gluckman PD, Feldman EL, Werther GA 2005 The insulin-like growth factor system and its pleiotropic functions in brain. Endocr Rev 26:916-943 (Pubitemid 41770158)
2. Firth SM, Baxter RC 2002 Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 23:824-854 (Pubitemid 35454590)
3. LeRoith D, Roberts Jr CT 2003 The insulin-like growth factor system and cancer. Cancer Lett 195:127-137 (Pubitemid 36588961)
4. Jones JI, Clemmons DR 1995 Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 16:3-34
5. Binoux M, Lalou C, Mohseni-Zadeh S 1999 Biological action of proteolytic fragments of IGF binding proteins. In: Rosenfeld RG, Roberts CTJ, eds. Contemporary endocrinology: the IGF system. Totowa, NJ: Humana Press; 281-313
6. Russo VC, Rekaris G, Baker NL, Bach LA, Werther GA 1999 Basic fibroblast growth factor induces proteolysis of secreted and cell membrane-associated insulin-like growth factor binding protein-2 in human neuroblastoma cells. Endocrinology 140:3082-3090 (Pubitemid 30650622)
7. Reeve JG, Morgan J, Schwander J, Bleehen NM 1993 Role for membrane and secreted insulin-like growth factor-binding protein-2 in the regulation of insulin-like growth factor action in lung tumors. Cancer Res 53:4680-4685 (Pubitemid 23304400)
8. Arai T, Busby Jr W, Clemmons DR 1996 Binding of insulin-like growth factor (IGF) I or II to IGF-binding protein-2 enables it to bind to heparin and extracellular matrix. Endocrinology 137:4571-4575 (Pubitemid 26403291)
9. Russo VC, Bach LA, Fosang AJ, Baker NL, Werther GA 1997 Insulin-like growth factor binding protein-2 binds to cell surface proteoglycans in the rat brain olfactory bulb. Endocrinology 138:4858-4867 (Pubitemid 27460925)
10. Marinaro JA, Neumann GM, Russo VC, Leeding KS, Bach LA 2000 O-glycosylation of insulin-like growth factor (IGF) binding protein-6 maintains high IGF-II binding affinity by decreasing binding to glycosaminoglycans and susceptibility to proteolysis. Eur J Biochem 267:5378-5386
11. Perks CM, Newcomb PV, Norman MR, Holly JM 1999 Effect of insulin-like growth factor binding protein-1 on integrin signalling and the induction of apoptosis in human breast cancer cells. J Mol Endocrinol 22:141-150 (Pubitemid 29193102)
12. Pereira JJ, Meyer T, Docherty SE, Reid HH, Marshall J, Thompson EW, Rossjohn J, Price JT 2004 Bimolecular interaction of insulin-like growth factor (IGF) binding protein-2 with αvβ3 negatively modulates IGF-I-mediated migration and tumor growth. Cancer Res 64:977-984 (Pubitemid 38176900)
13. Schütt B, Langkamp M, Rauschnabel U, Ranke M, Elmlinger MW 2004 Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J Mol Endocrinol 32:859-868
14. Oh Y, Müller HL, Lamson G, Rosenfeld RG 1993 Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem 268:14964-14971 (Pubitemid 23206645)
15. Leal SM, Liu Q, Huang SS, Huang JS 1997 The type V transforming growth factor β receptor is the putative insulin-like growth factor-binding protein 3 receptor. J Biol Chem 272:20572-20576 (Pubitemid 27355615)
16. Yamanaka Y, Fowlkes JL, Wilson EM, Rosenfeld RG, Oh Y 1999 Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule. Endocrinology 140:1319-1328
17. Andress DL 1995 Heparin modulates the binding of insulin-like growth factor (IGF) binding protein-5 to a membrane protein in osteoblastic cells. J Biol Chem 270:28289-28296
18. Andress DL 1998 Insulin-like growth factor-binding protein-5 (IGFBP-5) stimulates phosphorylation of the IGFBP-5 receptor. Am J Physiol 274(Pt 1):E744-E750
19. Schedlich LJ, O'Han MK, Leong GM, Baxter RC 2004 Insulin-like growth factor binding protein-3 prevents retinoid receptor heterodimerization: implications for retinoic acid-sensitivity in human breast cancer cells. Biochem Biophys Res Commun 314:83-88 (Pubitemid 38058372)
20. Schedlich LJ, Muthukaruppan A, O'Han MK, Baxter RC 2007 Insulin-like growth factor binding protein-5 interacts with the vitamin D receptor and modulates the vitamin D response in osteoblasts. Mol Endocrinol 21:2378-2390 (Pubitemid 47529352)
21. Iosef C, Gkourasas T, Jia CY, Li SS, Han VK 2008 A functional nuclear localization signal in insulin-like growth factor binding protein-6 mediates its nuclear import. Endocrinology 149:1214-1226 (Pubitemid 351397939)
22. Iosef C, Vilk G, Gkourasas T, Lee KJ, Chen BP, Fu P, Bach LA, Lajoie G, Gupta MB, Li SS, Han VK 2010 Insulin-like growth factor binding protein-6 (IGFBP-6) interacts with DNA-end binding protein Ku80 to regulate cell fate. Cell Signal 22:1033-1043
23. Liu B, Lee HY, Weinzimer SA, Powell DR, Clifford JL, Kurie JM, Cohen P 2000 Direct functional interactions between IGFBP-3 and RXR-a regulate transcriptional signalling and apoptosis. J Biol Chem 2000 Jun 28
24. Schedlich LJ, Le Page SL, Firth SM, Briggs LJ, Jans DA, Baxter RC 2000 Nuclear import of insulin-like growth factor-binding protein-3 and -5 is mediated by the importin β subunit. J Biol Chem 275:23462-23470 (Pubitemid 30624626)
25. Russo VC, Schütt BS, Andaloro E, Ymer SI, Hoeflich A, Ranke MB, Bach LA, Werther GA 2005 Insulin-like growth factor binding protein-2 binding to extracellular matrix plays a critical role in neuroblastoma cell proliferation, migration, and invasion. Endocrinology 146:4445-4455 (Pubitemid 41324043)
26. Zumkeller W, Westphal M 2001 The IGF/IGFBP system in CNS malignancy. Mol Pathol 54:227-229 (Pubitemid 32730397)
27. Elmlinger MW, Deininger MH, Schuett BS, Meyermann R, Duffner F, Grote EH, Ranke MB 2001 In vivo expression of insulin-like growth factor-binding protein-2 in human gliomas increases with the tumor grade. Endocrinology 142:1652-1658 (Pubitemid 32299696)
28. Moore MG, Wetterau LA, Francis MJ, Peehl DM, Cohen P 2003 Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells. Int J Cancer 105:14-19 (Pubitemid 36418479)
29. Flyvbjerg A, Mogensen O, Mogensen B, Nielsen OS 1997 Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: Correlation with cancer antigen 125 and tumor-associated trypsin inhibitor. J Clin Endocrinol Metab 82:2308-2313
30. Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR, Rosenfeld RG 1993 Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab 76:1031-1035 (Pubitemid 23110857)
31. Fukushima T, Tezuka T, Shimomura T, Nakano S, Kataoka H 2007 Silencing of insulin-like growth factor-binding protein-2 in human glioblastoma cells reduces both invasiveness and expression of progression-associated gene CD24. J Biol Chem 282:18634-18644 (Pubitemid 47100243)
32. Diehl D, Hessel E, Oesterle D, Renner-Müller I, Elmlinger M, Langhammer M, Göttlicher M, Wolf E, Lahm H, Hoeflich A 2009 IGFBP-2 overexpression reduces the appearance of dysplastic aberrant crypt foci and inhibits growth of adenomas in chemically induced colorectal carcinogenesis. Int J Cancer 124:2220-2225
33. Hoeflich A, Reisinger R, Schuett BS, Elmlinger MW, Russo VC, Vargas GA, Jehle PM, Lahm H, Renner-Müller I, Wolf E 2004 Peri/nuclear localization of intact insulin-like growth factor binding protein-2 and a distinct carboxyl-terminal IGFBP-2 fragment in vivo. Biochem Biophys Res Commun 324:705-710
34. Terrien X, Bonvin E, Corroyer S, Tabary O, Clement A, Henrion Caude A 2005 Intracellular colocalization and interaction of IGF-binding protein-2 with the cyclin-dependent kinase inhibitor p21CIP1/WAF1 during growth inhibition. Biochem J 392:457-465 (Pubitemid 43022724)
35. Miyako K, Cobb LJ, Francis M, Huang A, Peng B, Pintar JE, Ariga H, Cohen P 2009 PAPA-1 is a nuclear binding partner of IGFBP-2 and modulates its growth-promoting actions. Mol Endocrinol 23:169-175
36. Suter DM, Cartier L, Bettiol E, Tirefort D, Jaconi ME, Dubois-Dauphin M, Krause KH 2006 Rapid generation of stable transgenic embryonic stem cell lines using modular lentivectors. Stem Cells 24:615-623 (Pubitemid 44464765)
37. Higgins S, Wong SH, Richner M, Rowe CL, Newgreen DF, Werther GA, Russo VC 2009 Fibroblast growth factor 2 reactivates G1 checkpoint in SK-N-MC cells via regulation of p21, inhibitor of differentiation genes (Id1-3), and epithelium-mesenchyme transition-like events. Endocrinology 150:4044-4055
38. Russo VC, Andaloro E, Fornaro SA, Najdovska S, Newgreen DF, Bach LA, Werther GA 2004 Fibroblast growth factor-2 over-rides insulin-like growth factor-I induced proliferation and cell survival in human neuroblastoma cells. J Cell Physiol 199:371-380 (Pubitemid 38580433)
39. Mukhopadhyay D, Knebelmann B, Cohen HT, Ananth S, Sukhatme VP 1997 The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 17:5629-5639 (Pubitemid 27357659)
40. Ribatti D, Nico B, Vacca A, Presta M 2006 The gelatin sponge-chorioallantoic membrane assay. Nat Protoc 1:85-91
41. Airoldi I, Di Carlo E, Cocco C, Taverniti G, D'Antuono T, Ognio E, Watanabe M, Ribatti D, Pistoia V 2007 Endogenous IL-12 triggers an antiangiogenic program in melanoma cells. Proc Natl Acad Sci USA 104:3996-4001 (Pubitemid 47181567)
42. Rangel-Moreno J, Hartson L, Navarro C, Gaxiola M, Selman M, Randall TD 2006 Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest 116:3183-3194 (Pubitemid 44878632)
43. Chen N, Ye XC, Chu K, Navone NM, Sage EH, Yu-Lee LY, Logothetis CJ, Lin SH 2007 A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res 67:6544-6548 (Pubitemid 47105497)
44. Deryugina E, Quigley J 2006 Matrix metalloproteinases and tumor metastasis. Cancer Metast Rev 25:9-34 (Pubitemid 43723979)
45. Liu J, Uygur B, Zhang Z, Shao L, Romero D, Vary C, Ding Q, Wu WS 2010 Slug inhibits proliferation of human prostate cancer cells via downregulation of cyclin D1 expression. Prostate 70:1768-1777
46. Ross JS, Kaur P, Sheehan CE, Fisher HA, Kaufman Jr RA, Kallakury BV 2003 Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod Pathol 16:198-205 (Pubitemid 36337424)
47. Gentner B, Wein A, Croner RS, Zeittraeger I, Wirtz RM, Roedle F, Dimmler A, Dorlaque L, Hohenberger W, Hahn EG, Brueckl WM 2009 Differences in the gene expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in primary colorectal tumors and their synchronous liver metastases. Anticancer Res 29:67-74
48. Sund M, Xie L, Kalluri R 2004 The contribution of vascular basement membranes and extracellular matrix to the mechanics of tumor angiogenesis. APMIS 112:450-462 (Pubitemid 39626053)
49. Poomthavorn P, Wong SH, Higgins S, Werther GA, Russo VC 2009 Activation of a prometastatic gene expression program in hypoxic neuroblastoma cells. Endocr Relat Cancer 16:991-1004
50. Schäfer G, Cramer T, Suske G, Kemmner W, Wiedenmann B, Höcker M 2003 Oxidative stress regulates vascular endothelial growth factor-A gene transcription through Sp1- and Sp3-dependent activation of two proximal GC-rich promoter elements. J Biol Chem 278:8190-8198 (Pubitemid 36800562)
51. Wraight CJ, Liepe IJ, White PJ, Hibbs AR, Werther GA 1998 Intranuclear localization of insulin-like growth factor binding protein-3 (IGFBP-3) during cell division in human keratinocytes. J Invest Dermatol 111:239-242 (Pubitemid 28354710)
52. Meyer T, Hart IR 1998 Mechanisms of tumour metastasis. Eur J Cancer 34:214-221 (Pubitemid 28189189)
53. Katoh M 2005 Epithelial-mesenchymal transition in gastric cancer (review). Int J Oncol 27:1677-1683
54. Cano CE, Motoo Y, Iovanna JL 2010 Epithelial-to-mesenchymal transition in pancreatic adenocarcinoma. TheScientificWorld-JOURNAL 10:1947-1957
55. Kuniyasu H, Ellis LM, Evans DB, Abbruzzese JL, Fenoglio CJ, Bucana CD, Cleary KR, Tahara E, Fidler IJ 1999 Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma. Clin Cancer Res 5:25-33 (Pubitemid 29045174)
56. Hung JJ, Yang MH, Hsu HS, Hsu WH, Liu JS, Wu KJ 2009 Prognostic significance of hypoxia-inducible factor-1α, TWIST1 and Snail expression in resectable non-small cell lung cancer. Thorax 64:1082-1089
57. Sulzer MA, Leers MP, Van Noord JA, Bollen EC, Theunissen PH 1998 Reduced E-cadherin expression is associated with increased lymph node metastasis and unfavorable prognosis in non-small cell lung cancer. Am J Respir Crit Care Med 157:1319-1323
58. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, Thompson EW 2007 Epithelial - Mesenchymal and mesenchymal - epithelial transitions in carcinoma progression. J Cell Physiol 213:374-383 (Pubitemid 47509716)
59. Wallerand H, Robert G, Pasticier G, Ravaud A, Ballanger P, Reiter RE, Ferrière J-M The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers. Urol Oncol-Semin Ori 28:473-479
60. Guo DL, Zhang J, Yuen ST, Tsui WY, Chan AS, Ho C, Ji J, Leung SY, Chen X 2006 Reduced expression of EphB2 that parallels invasion and metastasis in colorectal tumours. Carcinogenesis 27:454-464 (Pubitemid 43372874)
61. Li HC, Cao DC, Liu Y, Hou YF, Wu J, Lu JS, Di GH, Liu G, Li FM, Ou ZL, Jie C, Shen ZZ, Shao ZM 2004 Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat 88:75-85 (Pubitemid 39524447)
62. Peruzzi D, Mori F, Conforti A, Lazzaro D, De Rinaldis E, Ciliberto G, La Monica N, Aurisicchio L 2009 MMP11: A novel target antigen for cancer immunotherapy. Clin Cancer Res 15:4104-4113